The greatest therapeutic benefit of radiotherapy is achieved by depositing the highest dose in the treated tissue by keeping the nearby organs’ doses below established limits. The Clinac iX, clinical linear accelerator manufactured by Varian Inc., present at the Department of Medical Physics of the Instituto de Cáncer Carlos Ardila Lülle in the University Hospital of the Fundacion Santa Fe de Bogotá allows the application of three different techniques for external radiotherapy treatments, being the conformational technique the routinely one used for the hypofractionated treatment in breast volume (4005 cGy / 267 cGy in 15 sessions) with sequential scaled boost in the bed surgical area (5 additional sessions of 200 cGy). With the intention of using the modulation techniques and applying the integrated simultaneous boost (synchronously in 15 sessions deposit 4005 cGy / 267 cGy in breas volume and 4500 cGy / 300 cGy within the boost volume ) this evaluation was carried out using the Gay model and Niemierko to determine theTumor Control Probability and the Normal Tissue Complication Probability from the calculation of the Equivalent Uniform Dose made with the dose distributions determined by the EclipseTMtreatment planning system of Varian Inc.. With the endorsement of the Ethics Committee and the Subdirection of Clinical Studies of the University Hospital, images of tomographic simulations (8 patients referred to the service) were used to project 5 treatment schedules that meet the homogeneity criteria (HI < 0.1) and conformation (CI > 0.9) of the center, being the arcotherapy with simultaneous boost slightly the best dose conformation (2%). The comparison between the di erent techniques showed that the reduction in total treatment time slightly reduces the tumor control in the breast, but keeps it in the boost zone when the integrated boost is applied with the modulated intensity techniques; although arcotherapy irradiations increase the dose received by the contralateral organs, the clinical e ects will not be significant in the integrated scheme but in the sequential one, where the increase, from 5% to 10%, of the probability of having symptomatic pneumonitis.